




Intravenous glutamine supplementation is standard care when parenteral nutrition is given for critical illness. There
are data of a reduced mortality when glutamine supplementation is given. In addition, standard commercial
products for parenteral nutrition do not contain any glutamine due to glutamine instability in aqueous solutions.
For the majority of critical ill patients who are fed enterally, the available evidence is insufficient to recommend
glutamine supplementation. Standard formulation of enteral nutrition contains some glutamine: 2-4 g/L. However,
this dose is insufficient to normalize glutamine plasma concentration.
Plasma concentration of glutamine is low in many patients with critical illness and a low level is an independent
risk factor for mortality. A low plasma glutamine concentration is the best indicator of glutamine depletion. Data
are emerging about how the endogenous production of glutamine is regulated. We know that skeletal muscle is
the major producer of glutamine and that a part of the profound depletion of skeletal muscle seen in critical
illness is a reflection of the need to produce glutamine.
Glutamine is utilized in rapidly dividing cells in the splanchnic area. Quantitatively most glutamine is oxidized, but
the availability of glutamine in surplus is important for the de novo synthesis of nucleotides and necessary for cell
division and protein synthesis. More knowledge about the regulation of the endogenous production of glutamine
is needed to outline better guidelines for glutamine supplementation in the future.
Recommendation
Presently the recommendation from ESPEN and
ASPEN/SCCM is to add intravenous (IV) glutamine
supplementation when total parenteral nutrition (TPN)
is given to critically ill patients [1-3]. In all guidelines,
this is given a level A recommendation. This evidence is
based on several meta-analyses, and the recommenda-
tions also include a dose of glutamine of 0.3-0.5 g/kg/
day. This dose will normalize plasma glutamine concen-
tration in almost all critically ill patients [4,5].
The problem arises when the patients are fed differ-
ently than by TPN. This includes enteral nutrition, com-
bined enteral and parenteral nutrition, and hypocaloric
nutrition. An insufficient dose of glutamine may be
added to these states. In all these settings, the existing
evidence is less conclusive.
Route of food administration
Many colleges, investigators, and opinion-leaders feel
that the route of nutrient administration makes a dif-
ference in critically ill patients. Usually the opinion is
that enteral nutrition is superior to parenteral nutri-
tion. This is probably true for infectious complications
in patients randomized to enteral or parenteral nutri-
tion, but no studies or meta-analyses demonstrate a
mortality difference [6-10]. In fact the meta-analysis
that demonstrates a difference, does so in favor of par-
enteral nutrition [10].
Numerous arguments may be given about why the
design of studies that support the existing meta-analyses
are not adequate: for example, only patients with a func-
tional gastrointestinal tract were included; no glucose
control; different caloric intake in groups; no dropout
information; no blinding.
In the existing scoring systems for outcomes, there is
no marker for gastrointestinal function. This is largely
related to the absence of a suitable surrogate parameter
for scoring. On the other hand, there is solid informa-
tion that a successful enteral feeding, indicative of a
functional gastrointestinal tract, is a predictor for a
favorable outcome in patients with a similar mortality
risk as estimated from the conventional scoring systems
[2,11,12]. Success of enteral feeding may be enhanced by
technical or pharmaceutical techniques, but presently
there is very little evidence that such enhancement gives
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provided the original work is properly cited.an outcome benefit even if it makes enteral nutrition
more successful [13].
Route of glutamine administration
As stated earlier, IV glutamine supplementation of 0.3-
0.5 g/kg/day provides an improved outcome for patients
on TPN [14-17]. This corresponds to an exogenous glu-
tamine supplementation of 20-30 g/day, which nor-
malizes the plasma concentration in most critcally ill
patients [4,5]. Healthy subjects have an endogenous glu-
tamine production of 50-80 g/day [18-21]. Most of the
de novo glutamine synthesis takes place in skeletal mus-
cle and is thereafter exported to the splanchnic area to
be used mostly in enterocytes and immune cells [22,23].
In the critically ill, glutamine production is not altered,
but the production is insufficient to keep up the plasma
concentration [20,24,25].
IV glutamine supplementation results in a uniform
uptake of glutamine across the splanchnic area, similar
to what happens with the endogenously produced gluta-
mine. IV administration of glutamine is well character-
ized and the elimination rate from plasma is fast [4].
This pharmacokinetic profile makes it preferable to use
a constant infusion for the IV glutamine supplementa-
tion. This may be as an additive to the parenteral nutri-
tion or as a separate IV infusion of glutamine. In the
latter case, this may be administered in a central or per-
ipheral vein [26]. If a commercially available 20% gluta-
mine containing dipeptide solution is used, the
osmolarity is high (approximately 900 mosm/L); how-
ever, because the pH is neutral, this does not irritate the
peripheral veins.
In the case of enteral glutamine supplementation, the
kinetics is much less well characterized [27]. Overall,
the uptake of crystalline or dipeptide glutamine is fast
and occurs in the upper part of the jejunum [18,28].
Only a fraction of the absorbed glutamine can be recov-
ered in the portal blood. This is indicative of elimination
in the gut, most likely in the enterocytes and immune
cells present there. From portal blood through the liver
into the systemic circulation another fraction of the
absorbed glutamine is utilized in the liver. Therefore,
the so-called first “pass elimination” is substantial: 40-
90%. It may be argued that this uptake is adequate, that
the enterocytes and the immune cells actually are the
targets for the endogenous glutamine production [22].
This is true, but at the same time, the complete uptake
of the enterally administered glutamine in the upper
part of the jejunum leaves the remaining part of the gas-
trointestinal tract unsupported by the enteral route. The
effect on plasma glutamine concentration of an enterally
administered glutamine supplementation is marginal
[29-31]. So, after enteral glutamine supply, the low
plasma concentration in critically ill is still low. It is
highly likely that when enteral nutrition is not possible,
as u p p l yo fp a r e n t e r a l l ya dministered glutamine
becomes critical for the intestine. This may to some
extent be compensated for by other amino acids when
enteral nutrition is functional.
Level of feeding
The studies that demonstrate a favorable effect of gluta-
mine are all studies where patients are fed according to
their measured or estimated energy expenditure
[14,15,17]. This is one possible explanation why studies
with enterally supplemented patients on enteral nutri-
tion have not been conclusive. For patients on parent-
eral nutrition, there are no reports employing a
hypocaloric nutrition supplemented with glutamine.
It is well known that overfeeding critically ill patients
may cause harm [2,32]. Overfeeding most often is prac-
tised when parenteral nutrition is given. Today this may
be when large doses of lipid emulsion are given as a
vehicle for drugs, or when enteral and parenteral nutri-
tion is combined and the two routes of administration
are not cleared between each other properly. Still if the
caloric support is decided according to body weight, a
considerable overfeeding may happen in individual
cases. Adding glutamine supplementation may further
boost the overfeeding. Measuring the energy expendi-
ture by indirect calorimetry decreases the risk of over-
feeding and enhances the quality of care in the ICU
[33,34].
Plasma concentration
The fact that glutamine deficiency defined as a low
plasma concentration at ICU admittance is an indepen-
dent mortality predictor [35,36] makes it mandatory
that future studies of exogenous glutamine supplemen-
tation define the patient groups studied in terms of glu-
tamine deficiency. The original finding by Oudemans-
Van Straaten et al. has been confirmed by subsequent
studies [35]. It is true that plasma concentration is a
poor indicator of intracellular depletion [37], which
occurs postoperatively and in critical illness [5,38-40].
This depletion is however not uniform, but different in
different cell types [41,42]. A conditional deficiency, as
has been suggested, is best characterized by the plasma
concentration. During the duration of ICU stay, plasma
concentration only changes marginally [5].
To better define the degree of glutamine depletion
and to enable a more precise selection of the patients in
need of exogenous glutamine supplementation is neces-
sary to be able to design study protocols that will give
conclusive evidence [43]. The heterogeneity in patient
groups studied, in particular studies of enteral supple-
mentation, may be a major factor behind the inconclu-
sive results [16].
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determiner of glutamine depletion [35,36]. It is usually
available and is related to outcome. There is no direct
solid knowledge that normalization of plasma glutamine
is associated with a better outcome; more than that we
know that in the combined group of patients with a
normal and/or a normalized plasma glutamine concen-
tration there is a better outcome. More knowledge
about the endogenous production of glutamine related
to outcome and related to plasma glutamine concentra-
tion is needed, in particular when glutamine supplemen-
tation is given enterally.
Possible adverse effects related to glutamine
supplementation
The only group of patients in the ICU with supranormal
plasma glutamine concentration are patients with acute
fulminant liver failure [44]. In contrast patients with
chronic liver failure or acute-on-chronic liver failure
have low or normal plasma glutamine concentrations
and therefore they may be treated as any other patient
in the ICU. On the other hand, the patient with acute
fulminant liver failure may deserve some caution.
Usually the history of disease is short and no malnutri-
tion is at hand, therefore the indication for nutritional
intervention is relative. The focus is usually on whether
there will be a spontaneous remission or whether an
acute liver transplantation will be needed. This decision
is usually reached within a few days, so this group of
patients does not constitute any major problem. A sub-
group–insufficiently studied at present–are patients with
acute liver failure after a liver resection with superven-
ing complications. Here, we presently withhold gluta-
mine supplementation waiting for more data.
Head trauma patients and other neurosurgical patients
are another group that has been discussed because of
the high interstitial concentration of glutamate, which in
some observational studies have been associated with
worse outcomes. The high interstitial glutamate concen-
tration is mainly reported when microdialysis is done in
the so-called penumbra zone, where there is an
enhanced cell leakage. Glutamate is an excitatory trans-
mitter and may therefore have effects in itself. In the
intact brain, released glutamate is reabsorbed into nerve
endings and is reutilized or taken up by astroglia and
metabolized into glutamine. Hence, the brain is a net
exporter of glutamine. When a supplementation dose of
glutamine, on the level of the general recommendation,
is given to head trauma patients, no change in the gluta-
mate concentration of the microdialysis fluid can be
detected [24]. Furthermore, there is no change in the
net balance of glutamine or glutamine across the brain
during supplementation [45]. Therefore, fear of an
increase of cerebral interstitial glutamine concentration
is no reason to abstain from glutamine supplementation.
The predicted value of low plasma glutamine concentra-
tion or the value of glutamine supplementation on out-
come has to our knowledge not been investigated in this
particular patient group.
During dialysis or ultrafiltration, small molecules are
lost to a higher degree compared with when urine is
produced in a healthy kidney. Therefore, the question
has been raised whether IV-supplemented glutamine
will be lost in the dialysate in particular during continu-
ous renal replacement therapy (CRRT), when the filtra-
tion is working around the clock. A recent study
showed that all amino acids are lost during CRRT but
not glutamine in particular [25]. Nevertheless, when
CRRT is necessary the supplementation of glutamine
should if anything be a little higher than usual: 0.5 g/kg/
day rather than 0.3 g/kg/day.
Comments on individual studies
Two single-center studies provide the bulk of evidence
for the recommendation to give IV glutamine supple-
mentation when TPN is given [14,15]. Both studies are
o fg o o dq u a l i t ya n di n v o l v em a i n l ym u l t i p l eo r g a nf a i l -
ure patients with a longer ICU stay, but they were per-
formed more than 10 years ago. Both studies show the
same pattern, that a tendency toward a reduction in
mortality during ICU stay became statistically significant
as all-cause 6-month mortality. Both studies were com-
paratively small (n < 100) and no glucose control was
used in the clinical practice at that time. Other studies
that are included in the present meta-analyses are of
small size or include critically ill patients only as a part
of the total patient material [16]. An overview of the
cited studies is given in Table 1.
Studies of enterally administered glutamine supple-
mentation to patients fed by enteral nutrition comprise
a much more heterogenic patient group [29,30,46-50].
There are studies of exclusively trauma patients or burn
patients, or there are studies that include a broad spec-
trum of critically ill patients with a wide range of diag-
noses and consequently a very variable ICU length of
stay. Not surprisingly the meta-analysis shows no mor-
tality advantage but in many individual studies a mor-
bidity advantage [16]. These studies represent an
interpretation problem in several respects; in many
cases a hypocaloric feeding, uncertainty concerning the
utilization of the given supplementation, sometimes a
considerable dilution effect from many included short-
stayers with a low mortality rate, and a short treatment
period [48].
An interesting study with a different concept uses an
enteral product with key nutrients, including 30 g of
glutamine per day. Some studies employing this product
are small in size and mainly focus on safety [51]. One
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administration of this product was possible, demon-
strates an improvement in sequential SOFA scoring
[29]. This is the most encouraging finding from enteral
administration of glutamine supplementation.
A recent study in Scotland, the SIGNET trial, is the
largest (n = 502) study of glutamine supplementation to
critically ill patients to date [52,53]. The primary out-
come variable was infection rate, and no benefit attribu-
table to the glutamine supplementation was seen. Some
concerns about the protocol have been addressed. Glu-
tamine supplementation of 20 g was added into the all-
in-one bag containing 2,000 kcal used for parenteral
nutrition. Patients were given IV nutrition from this bag
whilst the enteral nutrition started in parallel. When
more than 50% of the individual caloric target was given
as enteral nutrition, the parenteral glutamine containing
component was stopped. The result was short-term
treatment (mean 5 days), and a low, not well-defined
dose of glutamine. In addition, the treatment period was
limited to a maximum of 10 days. The obvious limita-
tions from the study make the negative result difficult to
interpret.
A Scandinavian glutamine study also has been pub-
lished recently [17]. In this study, the IV glutamine sup-
plementation was given separate from the nutrition.
Supplementation continued as long as patients stayed in
t h eI C U .P a t i e n t sw e r ef u l l yf e dd u r i n gt h ee n t i r eI C U
period, in most cases using a combination of enteral
and parenteral nutrition. Primary outcome variable was
ad i f f e r e n c ei nS O F As c o r i n g .T h es t u d yw a sp l a n n e d
for 1,000 patients, but was interrupted at 410 due to
slow recruitment after 4 years. Primary outcome was
not conclusive, but as secondary outcome ICU mortality
was reduced in the treatment group. This reduction
was, however, not sustained as 6-month all-cause mor-
tality. This study is the first to combine enteral and
parenteral nutrition. It may be hypothesized from the
observation of an ICU mortality effect that continuation
of glutamine supplementation also post-ICU may bring
an outcome benefit.
In the pipeline there is a large North American-Eur-
opean study combining key nutrients, glutamine, and
antioxidants, and combining enteral and parenteral
routes for supplementation [54]. Results may be
expected 1-2 years from now.
Conclusions
IV glutamine supplementation is standard care when
parenteral nutrition is given in critical illness. For the
majority of critical ill patients who are fed enterally,
there is insufficient evidence for recommendations pre-
sently. Plasma concentration of glutamine is an indepen-
dent risk factor for mortality in critical illness. So far,
low plasma glutamine concentration is the best indicator
of glutamine depletion. More knowledge about how the
endogenous production of glutamine is regulated is
needed to outline better guidelines for glutamine sup-
plementation in the future.
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